• Purpose : Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study has conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer. (dsmc.or.kr)
  • Conclusion : A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer. (dsmc.or.kr)
  • This randomized phase II trial studies paclitaxel and carboplatin to see how well they work compared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating patients with sex cord-ovarian stromal tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent). (clinicaltrialsgps.com)
  • I. To assess the activity of paclitaxel and carboplatin with respect to progression free survival (using bleomycin, etoposide, and cisplatin [BEP] as a reference) for newly diagnosed advanced or recurrent chemonaive ovarian sex cord-stromal tumors. (clinicaltrialsgps.com)
  • I. To estimate the toxicity of paclitaxel and carboplatin, and bleomycin, etoposide, and cisplatin in this patient population. (clinicaltrialsgps.com)
  • ARM II: Patients receive bleomycin sulfate IV on day 1 and etoposide phosphate* IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. (clinicaltrialsgps.com)
  • This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that has come back. (ucsf.edu)
  • A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. (ucsf.edu)
  • Background: the APICE study evaluates the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel-Nab-P) + gemcitabine (G) vs G alone in metastatic pancreatic cancer (MPC) from the Italian National Health Service (INHS) standpoint. (unisr.it)
  • Background/Aim: During recent years, a survival advantage was reported for first-line treatment of advanced pancreatic cancer with two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, over gemcitabine monotherapy. (iiarjournals.org)
  • Gemcitabine/nab-paclitaxel administration on days 1, 8 and 15 of a 4-week cycle is associated with some practical disadvantages. (iiarjournals.org)
  • Study combination included 1.5 g/m 2 gemcitabine and 175 mg/m 2 nab-paclitaxel given every 2 weeks. (iiarjournals.org)
  • Conclusion: Biweekly gemcitabine/nab-paclitaxel seems to have a similar safety and efficacy profile as the original regimen. (iiarjournals.org)
  • In addition, another randomized phase III trial (MPACT) reported the superiority of the combination of gemcitabine (1,000 mg/m 2 ) and nab-paclitaxel (125 mg/m 2 ) given on days 1, 8 and 15 of a 4-week cycle over gemcitabine monotherapy. (iiarjournals.org)
  • On this basis, we have adopted a biweekly regimen of the combination of gemcitabine and nab-paclitaxel with the same dose intensity in the first-line setting. (iiarjournals.org)
  • We performed a retrospective analysis of a prospectively collected database including all new patients with pancreatic cancer admitted to our clinic treated with biweekly gemcitabine in combination with nab-paclitaxel. (iiarjournals.org)
  • Patients received 175 mg/m 2 nab-paclitaxel followed by 1.5 g/m 2 gemcitabine on days 1 and 15, repeated every 28 days. (iiarjournals.org)
  • Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania. (news-medical.net)
  • Paclitaxel (brand name-Taxol) is an FDA-approved treatment for breast cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer (NSCLC). (ankr.us)
  • How should I take paclitaxel (Taxol)? (ankr.us)
  • What are the side effects of paclitaxel (Taxol)? (ankr.us)
  • Use the Ankr app or the myAnkr website help you track associated symptoms and decrease the side effects of paclitaxel (Taxol). (ankr.us)
  • Chang, AY , Garrow, GC, Hortobagyi, GN & Hohneker 1995, ' Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer ', Seminars in oncology , vol. 22, no. (johnshopkins.edu)
  • RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. (mayo.edu)
  • Conventional chemotherapy includes intravenous carboplatin and paclitaxel administered every 3 weeks for 6 cycles. (jnccn.org)
  • 3 , 4 The current therapy for ovarian cancer is debulking surgery followed by chemotherapy using carboplatin and paclitaxel (PTX). (nature.com)
  • To prospectively determine the incidence of carboplatin and paclitaxel hypersensitivity in these patients undergoing retreatment with both agents as first recurrence therapy. (ucsf.edu)
  • To identify molecular determinants that predict sensitivity or resistance to carboplatin and paclitaxel with or without bevacizumab followed with or without maintenance bevacizumab therapy. (ucsf.edu)
  • One-year follow-up was available in 98.7% of evaluable participants and five-year follow-up in 95%, which Gray noted represents an additional 3,355.5 patient years since a 2020 analysis by VIVA Physicians, in which investigators identified an absolute 4.6% increased mortality risk associated with paclitaxel-coated devices, albeit demonstrating a weaker mortality signal than was initially reported in December 2018 by Katsanos et al . (cardiovascularnews.com)
  • Although the trial wasn't designed to test whether the combination is more effective against breast tumors than paclitaxel, the patients' responses were promising. (news-medical.net)
  • By examining samples taken from a patient through the course of her treatment with palbociclib, the team found that as the tumors became resistant, the cells more than doubled their expression of several cell-cycle-driving genes, including PLK1, TOP2A, CDK1, and BUB1. (news-medical.net)
  • 1 - 3 In patients with node-negative small tumors, chemotherapy burden can be de-escalated by administering weekly paclitaxel for 3 months and concurrent trastuzumab for 1 year. (jnccn.org)
  • The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT). (stanfordhealthcare.org)
  • p53, mdm-2, p21, and mib-1 expression were assessed by immunohistochemical methods in primary tumors derived from 134 patients who took part in a randomized multicenter trial comparing docetaxel to sequential methotrexate and 5-fluorouracil (MF) in advanced breast cancer. (lu.se)
  • 3 Although myelosuppression is the major toxicity for docetaxel, 4 paclitaxel is more likely to be associated with dose-limiting peripheral neuropathy. (jnccn.org)
  • docetaxel, 42%) in small nonrandomized studies for patients who had not undergone prior chemotherapy for R/M HNSCC. (jnccn.org)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • Five fatal cases of neutropenic enterocolitis , inflammation of the mucosa of the small intestine and colon, have been reported in patients treated with docetaxel , French oncologists were informed in a letter dated February 15 by the ANSM (French National Drug and Health Product Safety Agency). (medscape.com)
  • The Institut Curie, in Paris, has stopped using docetaxel and replaced it with paclitaxel . (medscape.com)
  • The patients involved were 46 to 73 years old, and had been treated with a generic version of docetaxel ( Taxotere ) manufactured by the Indian pharmaceutical company Accord Healthcare (Intas Pharmaceuticals). (medscape.com)
  • The ANSM says that "no recommendation has been made to date, given the absence of additional investigative findings," but adds, "paclitaxel may be an alternative to docetaxel. (medscape.com)
  • However, in a press release dated February 16, 2017, the Institut Curie announced it was stopping use of docetaxel following the death of patients at several facilities in France. (medscape.com)
  • It says that on February 4, 2017, it reported to the ANSM the death of a patient following her first cycle of docetaxel. (medscape.com)
  • The incidence of febrile neutropenia/neutropenia with sepsis may also be higher in patients treated with trastuzumab in combination with docetaxel than in those treated with docetaxel alone. (medscape.com)
  • Frequent blood count monitoring should be conducted in all patients treated with docetaxel. (medscape.com)
  • Patients with febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m 2 for all subsequent cycles. (medscape.com)
  • p53, mdm-2, p21, and mib-1 expression were not significantly associated with response to chemotherapy, time to progression, or overall survival in the whole patient population or in the docetaxel group. (lu.se)
  • Pharmacokinetics were compared with respect to antiretroviral therapy and toxicity, Results: Thirty-four patients received paclitaxel, of whom 20 had no prior paclitaxel therapy and were assessable for response. (elsevierpure.com)
  • Conclusion: Despite higher exposure to paclitaxel, patients on protease inhibitors did not experience enhanced toxicity or efficacy. (elsevierpure.com)
  • The phase 1 part of the study determined the dose-limiting toxicity and the recommended dose of nivolumab, paclitaxel, and ramucirumab. (oncpracticemanagement.com)
  • The protocol treatment was discontinued in 5 patients due to toxicity. (oncpracticemanagement.com)
  • Paclitaxel-related toxicity occurred in 2 patients and 4 patients had nivolumab-related toxicities, with 1 also having toxicity due to paclitaxel. (oncpracticemanagement.com)
  • Dose-limiting toxicity (grade 4 neutropenia) occurred in two patients at level 2 (cycle I). Filgrastim was instituted thereafter with cycle I for the next four levels. (psu.edu)
  • Palbociclib effectively halts the cell cycle before that point, and thus in principle can synchronize cancer cells in a way that makes them more vulnerable to a closely following dose of paclitaxel. (news-medical.net)
  • The researchers ultimately settled on an optimal palbociclib dose of 75 mg per day, combined with a standard dose of paclitaxel. (news-medical.net)
  • With an initial fixed dose of paclitaxel 135 mg/m 2 given as a 24-hour infusion, carboplatin was administered in escalating doses in cohorts of three patients, based on a target area under the concentration-time curve (AUC) of 5, 7, 9, or 11 using Calvert's formula: dose (mg) = target AUC x (glomerular filtration rate + 25). (psu.edu)
  • Because these agents bind to distinct sites on tubulin and affect microtubules in opposite ways, a pilot study was conducted of the combination of vinorelbine end paclitaxel in patients with metastatic breast cancer or lung cancer who were refractory to first-line chemotherapy. (johnshopkins.edu)
  • The FDA has granted a priority review to a new drug application for oral paclitaxel and encequidar for use in patients with metastatic breast cancer. (onclive.com)
  • A total of 402 patients with metastatic breast cancer were enrolled to the randomized, controlled phase 3 trial . (onclive.com)
  • Athenex announces FDA acceptance for filing of US NDA for oral paclitaxel and encequidar in metastatic breast cancer with priority review. (onclive.com)
  • Athenex announces oral paclitaxel and encequidar had a significantly higher response rate over IV paclitaxel in a phase III pivotal study in metastatic breast cancer. (onclive.com)
  • That seemed better than what we would have expected from paclitaxel alone, but the only way to know the difference for certain is with a randomized clinical trial of the combination versus the single drug,' DeMichele said. (news-medical.net)
  • Nor did all-cause mortality differ by device type, be it paclitaxel-coated balloon versus plain balloon angioplasty, or drug-eluting stent versus bare-metal stent. (medscape.com)
  • To inform this decision, Gray and his co-investigators analysed randomised trials that evaluated FDA-approved paclitaxel-coated devices versus uncoated devices for the treatment of femoropopliteal artery disease, looking primarily at the mortality risk on an intention-to-treat basis, with key secondary analyses including dose/mortality and covariate interactions. (cardiovascularnews.com)
  • combined with bevacizumab/carboplatin/ paclitaxel (ABCP) versus bevacizumab/chemotherapy for patients with metastatic nonsquamous NSCLC. (jnccn.org)
  • Methods: Patients with advanced HIV-associated KS received paclitaxel (100 mg/m 2 ) by intravenous infusion over 3 h, and plasma samples were collected to measure paclitaxel concentration. (elsevierpure.com)
  • Nab-Paclitaxel is an intravenous chemotherapy used alone or in combination with other agents for the treatment of certain types of cancer. (nccs.com.sg)
  • Patients and methods: Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxle 100mg/m2 plus cisplatine 35mg/m2 on days 1 and 8 based on a 3-week cycle. (dsmc.or.kr)
  • The application was based on findings from a single pivotal phase 3 trial, which compared the use of encequidar and oral paclitaxel with intravenous (IV) paclitaxel monotherapy. (onclive.com)
  • In a phase II trial reported in JAMA Oncology by Debra L. Richardson, MD , of Stephenson Cancer Center, Oklahoma University Health Science Center, and colleagues, the addition of pazopanib (Votrient) to paclitaxel did not improve progression-free survival among women with persistent or recurrent ovarian cancer. (ascopost.com)
  • The investigators concluded: "The combination of pazopanib plus paclitaxel is not superior to paclitaxel in women with recurrent ovarian cancer. (ascopost.com)
  • Paclitaxel (PTX) is widely used for the treatment of ovarian cancer. (nature.com)
  • To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer , peritoneal primary or fallopian tube cancer. (ucsf.edu)
  • To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer. (ucsf.edu)
  • To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases quality of life (QOL) in patients with recurrent platinum-sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer, as measured by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) trial outcome index and Rand Short Form (SF)-36 physical functioning scale. (ucsf.edu)
  • To begin to test this concept in the clinic, DeMichele and colleagues, including lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology-Oncology in the Abramson Cancer Center, treated 27 breast cancer patients with alternating doses of palbociclib - administered daily for several days at a time - and paclitaxel administered once per week. (news-medical.net)
  • Eligible study patients were aged ≥20 years with an Eastern Cooperative Oncology Group performance status of 0 or 1 who were refractory to first-line chemotherapy consisting of platinum-fluoropyrimidine or who had disease recurrence >6 months after postoperative adjuvant chemotherapy. (oncpracticemanagement.com)
  • Patients and Methods: Patients with Eastern Cooperative Oncology Group performance status 0-2 diagnosed with advanced histologically or cytologically confirmed pancreatic cancer and no prior treatment were included in the study. (iiarjournals.org)
  • Despite progress in the field of oncology, the outcome of patients with metastatic disease remains poor ( 1 , 2 ). (iiarjournals.org)
  • All patients had to have Eastern Cooperative Oncology Group performance status ≤2, while no previous treatment for pancreatic cancer was allowed. (iiarjournals.org)
  • PURPOSE: The aim of this study was to evaluate if the occurrence of neutropenia is correlated with response to ramucirumab plus paclitaxel for metastatic gastric cancer. (bath.ac.uk)
  • METHODS: This is a retrospective study of patients treated with ramucirumab plus paclitaxel. (bath.ac.uk)
  • CONCLUSION: Our analysis seems to suggest that the occurrence of neutropenia predicts response to treatment with ramucirumab and paclitaxel. (bath.ac.uk)
  • abstract = "PURPOSE: The aim of this study was to evaluate if the occurrence of neutropenia is correlated with response to ramucirumab plus paclitaxel for metastatic gastric cancer.METHODS: This is a retrospective study of patients treated with ramucirumab plus paclitaxel.RESULTS: Fifty-three patients were evaluated. (bath.ac.uk)
  • Suitable treatment combinations have been investigated to determine if they convey survival benefits to patients with advanced gastric cancer, including an open-label, nonrandomized phase 1/2 study to evaluate the safety and efficacy of nivolumab with paclitaxel plus ramucirumab. (oncpracticemanagement.com)
  • This was combined with paclitaxel 80 mg/m 2 on days 1, 8, and 15 and ramucirumab 8 mg/kg on days 1 and 15 every 4 weeks. (oncpracticemanagement.com)
  • The combination of nivolumab with paclitaxel plus ramucirumab as second-line therapy in patients with advanced gastric cancer demonstrated promising responses with manageable treatment-related adverse events. (oncpracticemanagement.com)
  • Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. (oncpracticemanagement.com)
  • This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. (stanford.edu)
  • It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer. (stanford.edu)
  • Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
  • In assessments of recurrence/metastasis-free survival probability, high-levels of OTUD7B transcripts strongly predicted a poor prognosis and unfavorable response to paclitaxel-based chemotherapy in patients with TNBCs. (oncotarget.com)
  • Of the 20 patients assessable for response, 6 (30%) had an objective response and median progression-free survival was 7.8 months (95% confidence interval, 5.6, 21.0 months). (elsevierpure.com)
  • Patients with grade ≥3 neutropenia reported a progression-free survival of 6.6 months (95% confidence interval 3.3-8.4) and overall survival of 11 months (95% confidence interval 5.9-13.1) vs. 4.4 months (95% confidence interval 3.9-5.2) and 8.7 months (95% confidence interval 7.8-10.1) respectively in patients' group with lower grade events. (bath.ac.uk)
  • Median progression-free survival was 7.5 months in the combination group vs 6.2 months with paclitaxel alone (hazard ratio [HR] = 0.84, P = .20). (ascopost.com)
  • To estimate overall survival for paclitaxel and carboplatin relative to that of BEP. (clinicaltrialsgps.com)
  • The 5-year overall survival of patients with pancreatic cancer is approximately 5%, with potentially resectable disease representing the curable minority. (cancernetwork.com)
  • Even among patients who present with localized disease, the 5-year overall survival (OS) is approximately 20%, but potentially higher in patients with complete surgical resection (R0) and uninvolved lymph nodes. (cancernetwork.com)
  • At the July 25, 2019 data cutoff date, results illustrated a trend toward a progression-free survival advantage with the investigational regimen compared with IV paclitaxel ( P = .077). (onclive.com)
  • In this article, we review the data surrounding the use of chemotherapy (CT) and chemoradiotherapy (CRT) in patients with resectable pancreatic cancer. (cancernetwork.com)
  • Further therapeutic advances and prospective trials are needed to better define the optimal role of adjuvant and neoadjuvant treatment in patients with resectable pancreatic cancer. (cancernetwork.com)
  • However, there are some practical disadvantages associated with a weekly schedule, particularly in patients with poor performance status such as those with pancreatic cancer. (iiarjournals.org)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • We found that OTUD7B was downregulated in HCC38 but upregulated in MDA-MB436 cells after paclitaxel treatment at cytotoxic concentrations. (oncotarget.com)
  • Purpose: Paclitaxel, a cytotoxic agent metabolized by cytochrome P450 hepatic enzymes, is active for the treatment of human immunodeficiency (HIV) associated Kaposi's sarcoma. (elsevierpure.com)
  • The first three patients received vinorelbine 25 mg/m 2 intravenously for 5 to 10 minutes on days 1 and 8, and paclitaxel 90 mg/m 2 intravenously over 3 hours on day 1 after the administration of vinorelbine. (johnshopkins.edu)
  • Patients were assumed to receive intravenously Nab-P 125 mg/m2 + G 1000 mg/m2 on days 1, 8, and 15 every 4 weeks or G alone 1000 mg/m2 weekly for 7 out of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles) until progression. (unisr.it)
  • Patients and methods proportion of the patients will recur despite treatment with adjuvant polychemotherapy. (lu.se)
  • To assess the safety and early clinical results of a multicenter evaluation of airway bypass with paclitaxel-eluting stents for selected patients with severe emphysema. (nih.gov)
  • Thirty-five patients received the airway bypass procedure with a median of 8 stents implanted per patient. (nih.gov)
  • One week after the publication of a meta-analysis suggesting a signal of late deaths in patients treated with paclitaxel-coated balloons and stents for peripheral artery disease, two trials have been halted and leaders of the VIVA meeting have announced they will convene a special forum in the coming months to discuss the issue further. (tctmd.com)
  • As TCTMD reported , the meta-analysis by Konstantinos Katsanos, MD, PhD (Patras University Hospital, Rion, Greece), and colleagues, published in the Journal of the American Heart Association , examined data from 28 trials in which paclitaxel-coated balloons or stents were compared with uncoated balloon therapy for the treatment of lesions in the femoral and/or popliteal arteries. (tctmd.com)
  • one in patients with advanced cancer and brain metastases, and another in patients with recurrent malignant glioma. (wikipedia.org)
  • The combination of paclitaxel and carboplatin is active in non-small cell lung cancer, and the recommended phase II doses for the combination without filgrastim support are paclitaxel 175 mg/m 2 as a 24-hour infusion with the carboplatin dose based on a target AUC of 7. (psu.edu)
  • A second study (Abstract P4-13-04), to be presented Friday provides new clues to how breast cancer develops resistance to the palbociclib, a common occurrence among many patients who take the drug. (news-medical.net)
  • From the abstract: ' Is Ki-67 expression associated with the 21-gene recurrence score (RS) and with outcomes in patients with breast cancer with a low RS? (cdc.gov)
  • The high response rate we saw suggests this combination may hold benefits for patients over paclitaxel alone. (news-medical.net)
  • It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer. (ucsf.edu)
  • Results showed that that the combination of encequidar and oral paclitaxel elicited a statistically significant overall response rate (ORR) compared with IV paclitaxel in this population, meeting the primary end point of the trial. (onclive.com)
  • It can be used in combination with paclitaxel for the treatment of esophageal cancer, which is an off-label indication. (medscape.com)
  • The regimen is considered feasible if patients are able to complete the paclitaxel, trastuzumab, and lapatinib (THL) portion of the regimen without a dose delay or reduction or grade 3 or greater QTc prolongation. (her2support.org)
  • This study thus investigated the potential effect of paclitaxel combined with wilfortrine on cultured liver cancer cells and related mechanisms, in order to provide evidence for pathogenesis and treatment of liver cancer. (medscimonit.com)
  • Liver cancer cell line HpeG2 was divided into control, paclitaxel, wilfortrine, and combined treatment groups. (medscimonit.com)
  • The combined treatment using wilfortrine and paclitaxel can inhibit proliferation and invasion of liver cancer cells via down-regulating Bcl-2 and up-regulating Bax, with better efficacy than single use of either drug. (medscimonit.com)
  • No hint of increased mortality risk in association with the use of paclitaxel-coated devices for treatment of peripheral artery disease was detected in VOYAGER PAD, a multithousand-patient randomized trial with long-term follow-up and ascertainment of vital status in 99.6% of participants. (medscape.com)
  • Observers opined that the VOYAGER PAD findings effectively put to rest a nearly 2-year-old controversy over whether paclitaxel-coated devices for treatment of peripheral artery disease (PAD) carry an increased mortality risk. (medscape.com)
  • or other signs of infection during your treatment with paclitaxel (with polyoxyethylated castor oil) injection. (ankr.us)
  • Paclitaxel (oncogel) was under development for the treatment of esophageal cancer and recurrent glioma. (pharmaceutical-technology.com)
  • Molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed since paclitaxel resistance is still a clinical issue in treating TNBCs. (oncotarget.com)
  • We investigated the transcriptional profiling of consensus genes in HCC38 (paclitaxel-sensitive) and MDA-MB436 (paclitaxel-resistant) TNBC cells post-treatment with paclitaxel. (oncotarget.com)
  • In 2014, paclitaxel trevatide received orphan drug designation from FDA for the treatment of glioblastoma multiform As of January 2016, Angiochem has conducted phase II trials for the treatment of breast cancer with brain metastasis, glioblastoma, and high-grade glioma. (wikipedia.org)
  • no patients in the pazopanib group discontinued treatment due to hypertension. (ascopost.com)
  • Treatment related-adverse events grade ≥3 occurred in 90.7% of patients. (oncpracticemanagement.com)
  • While mortality rates for the two types of treatment were similar at 1 year, there was a 68% relative risk increase in all-cause death with paclitaxel-coated devices at 2 years and a 93% relative risk increase by 5 years compared with an uncoated-balloon approach. (tctmd.com)
  • The replacement marrow may be taken from the patient before treatment or may be donated by another person. (ucsfhealth.org)
  • This is because patients may present with a clinical scenario consistent with GCT (elevated serum tumor markers, testicular mass and retroperitoneal lymphadenopathy) with a concurrent life-threatening oncologic emergency that require immediate treatment. (stanfordhealthcare.org)
  • AFP ≥ 10,000 ng/mL - Patients who received prior radiation therapy (RT) for treatment of germ cell tumor are eligible for this study as long as there is evidence of progressive disease determined by tumor markers or other sites of metastases outside of the radiated site. (stanfordhealthcare.org)
  • OUTLINE: Patients are randomized to 1 of 2 treatment arms. (clinicaltrialsgps.com)
  • In the CRT arm, there were issues of compliance, with 32% of patients assigned to CRT receiving inappropriate radiation and 25% of patients failing to initiate treatment within 10 weeks post surgery, the protocol-specified time limit. (cancernetwork.com)
  • Patient characteristics at baseline were found to be well balanced between the 2 treatment arms. (onclive.com)
  • Neutropenia rates proved to be comparable between the 2 treatment arms, although more patients who received the encequidar regimen reported more grade 4 neutropenia and infection. (onclive.com)
  • Are you a patient looking for more information about urethral stricture treatment? (laborie.com)
  • Possible mechanisms for gram for breast cancer in southern Sweden issued 1991, pre- recurrence after treatment are low initial drug sensitivity or menopausal lymph node positive (N+) breast cancer patients an acquired drug resistance. (lu.se)
  • A male 13-year-old patient with chondroblastic osteosarcoma in the left distal thigh and acute lymphoblastic leukemia undergoing cancer treatment with methotrexate presented with severe oral mucositis. (bvsalud.org)
  • The monitoring and treatment of oral mucositis lesions in children and adolescents undergoing chemotherapy are necessary to prevent the patient from suffering from induced comorbidities. (bvsalud.org)
  • Moreover, oral mucositis induces pediatric patients to reduce food intake, which affects their nutritional status and makes them less responsive to treatment 4-5 . (bvsalud.org)
  • 5 reported that 78% of chemotherapy patients presented with mucositis at some point during treatment. (bvsalud.org)
  • According to the medical record, the patient had been undergoing cancer treatment for one year and eight months. (bvsalud.org)
  • Before the mucositis lesions appeared, the patient had been given a treatment protocol that included methotrexate (50mg) at 8-day intervals. (bvsalud.org)
  • At 3.5 years of follow-up, they had a 10.2% all-cause mortality rate, significantly less than the 13.5% rate in patients who didn't get a drug-coated device. (medscape.com)
  • Paclitaxel -containing devices (PTXDs) significantly reduce reintervention in patients with symptomatic femoropopliteal peripheral artery disease . (bvsalud.org)
  • care was associated with significantly improved OS in patients with disease progression on first-line chemotherapy. (jnccn.org)
  • Results of the first study found that palbociclib and paclitaxel can be safely combined on an alternating dosing schedule,' said Angela DeMichele, MD, MSCE, the Alan and Jill Miller Associate Professor in Breast Cancer Excellence in Penn's Abramson Cancer Center, and senior author on the study. (news-medical.net)
  • The study focused on a Penn Medicine patient who was first diagnosed with breast cancer in 1999. (news-medical.net)
  • Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o. (medscimonit.com)
  • As long as there are no safety concerns from the study monitors, I personally believe that all clinical studies need to continue, as they may provide invaluable evidence to decide on the safety and effectiveness of paclitaxel treatments in general. (tctmd.com)
  • Results : Fifty=-two patients were enrolled in the current study. (dsmc.or.kr)
  • The subsequent four patients enrolled in the study received the identical dose of vinorelbine, but the paclitaxel dose was increased to 175 mg/m 2 in the same sequence. (johnshopkins.edu)
  • Patients and study design. (iiarjournals.org)
  • Randomized pilot clinical study, with 35 patients assigned to two groups. (bvsalud.org)
  • In this cohort study of 2295 patients with breast cancer, a moderate correlation was observed between Ki-67 and RS. (cdc.gov)
  • This was a qualitative study, using semi-structured interviews with patients who underwent GS within a trial. (cdc.gov)
  • 1] Patients generally present with locally advanced or metastatic disease that precludes cure, since symptoms frequently prompt the diagnosis in the absence of effective screening strategies. (cancernetwork.com)
  • Patients with locally advanced/unresectable or metastatic histologically or cytologically proven pancreatic adenocarcinoma were eligible. (iiarjournals.org)
  • 2017;23:42-47 ) notes that neutropenic enterocolitis is a severe condition that usually affects immunocompromised patients. (medscape.com)
  • In a multicenter phase II trial, we prospectively evaluated the efficacy and tolerability of modified CBDCA plus weekly nab-PTX for elderly patients with untreated advanced NSCLC. (elsevierpure.com)
  • Conclusion.Modified CBDCA plus weekly nab-PTX demonstrated significant efficacy and acceptable toxicities in elderly patients with advanced NSCLC. (elsevierpure.com)
  • Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective St. (medscimonit.com)
  • Paclitaxel (with polyoxyethylated castor oil) injection may cause a large decrease in the number of white blood cells (a type of blood cell that is needed to fight infection) in your blood. (ankr.us)
  • Using the API 20NE case of F. novicida infection in a Thai patient who was un- (bioMérieux), the organism was identifi ed as Mannheimia dergoing chemotherapy. (cdc.gov)
  • Ulcers caused by oral mucositis can be an important source of systemic infection, especially in immunosuppressed patients 2-3 . (bvsalud.org)
  • Among these, 10 patients (26.5%) developed grade ≥3 neutropenia. (bath.ac.uk)
  • Although its exact pathogenesis is not completely understood, the main contributing factors appear to be intestinal mucosal injury together with neutropenia and the weakened immune system of the patient. (medscape.com)
  • Paclitaxel is a first-line chemotherapeutic for patients with breast cancer, particularly triple-negative breast cancer (TNBC). (oncotarget.com)
  • Results from the phase II trial in patients with breast cancer and leptomeningeal carcinomatosis, a fatal form of brain metastasis, were presented at ASCO in 2016. (wikipedia.org)
  • Two drugs, adriamycin and cytoxan, commonly used to treat breast cancer patients. (ucsfhealth.org)
  • Concurrent administration of vinorelbine end paclitaxel achieves synergistic cytotoxicity against MCF-7 and MDA-MB-231 breast cancer cells in vitro. (johnshopkins.edu)
  • Our data have provided evidence for a comparable prediction of clinical outcome in CMF-treated breast cancer patients using conventional clinical variables and gene expression based markers. (lu.se)
  • For example, when patients were enrolled into high-risk breast cancer surveillance programs for low/moderate risk breast cancer genes, they perceived the results to be very "useful" and of moderate-high utility. (cdc.gov)
  • In breast cancer patients, it is unclear whether measuring p53, mdm-2, or p21 expression provides information on how patients will respond to chemotherapy. (lu.se)
  • Specifically, the ORR achieved with the encequidar regimen was 36% compared with 24% with IV paclitaxel ( P = .01). (onclive.com)
  • Moreover, patients who received the encequidar regimen also experienced lower rates of alopecia, arthralgia, and myalgia. (onclive.com)
  • Results: Forty-six patients were treated with this regimen. (iiarjournals.org)
  • The Optilume® urethral drug-coated balloon was developed in response to severe patient and physician dissatisfaction with current stricture solutions. (laborie.com)
  • PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary. (mayo.edu)
  • Paclitaxel is a wide-spectrum anti-tumor agent, while wilfortrine has been shown to have an inhibitory effect on the proliferation of liver cancer cells. (medscimonit.com)
  • Paclitaxel (with polyoxyethylated castor oil) injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (ankr.us)
  • These findings suggest that OTUD7B may be a useful biomarker for predicting the anti-cancer effectiveness of paclitaxel and could serve as a new drug target for enhancing the canceridal efficiency of paclitaxel against TNBCs. (oncotarget.com)
  • This has then been shown to be a prospective cancer therapy drug that can not only be conjugated to paclitaxel but also peptides, monoclonal antibodies, siRNA and many other biological materials. (wikipedia.org)
  • It has been shown that cancer cell lines exposed to this hypoxic or serum-deprived condition will upregulate LRP1 expression, thus leading to an increased uptake of paclitaxel trevatide. (wikipedia.org)
  • no response was noted in the lung cancer patients. (johnshopkins.edu)
  • A National Cancer Data Base (NCDB) analysis of 1797 patients with vulvar cancer who underwent extirpative surgery with confirmed inguinal nodal involvement treated with adjuvant radiotherapy concluded that the addition of adjuvant chemotherapy resulted in a 38% reduction in mortality risk. (medscape.com)
  • We see oral paclitaxel as a potentially important alternative to IV infusions, especially during the current pandemic, as it may allow [patients with] cancer to take the oral chemotherapy at home. (onclive.com)
  • Radiotherapy was delivered to ipsilateral axil- cancer patients in the future, it is essential to increase our lary and supraclavicular lymph nodes and the remaining knowledge in mechanisms responsible for drug resistance, breast parenchyma after breast conservation surgery or tho- and to define reliable indicators for response to therapy. (lu.se)
  • The oral mucositis (OM) represents a frequent inflammatory condition in cancer patients, and poor oral hygiene has been related as a predisposing factor for its onset. (bvsalud.org)
  • We sought to explore patient-reported utility of all types of cancer results from genomic sequencing (GS). (cdc.gov)
  • Patients' perceptions of the utility of cancer GS results hinged on whether they triggered clinical action. (cdc.gov)
  • In contrast, patients receiving low/moderate risk or primary VUS results without clinical action perceived results as "concerning", leading to harms such as hypervigilance about cancer symptoms. (cdc.gov)
  • VOYAGER PAD was a double-blind, placebo-controlled clinical trial in which 6,564 patients undergoing lower-extremity revascularization for symptomatic PAD were randomized to rivaroxaban at 2.5 mg twice daily or placebo on top of background low-dose aspirin. (medscape.com)
  • The process of getting patients onto a clinical trial, or the number of patients planned for a given trial. (ucsfhealth.org)
  • Forty-three patients were enrolled in this clinical trial comparing outcomes of surgery alone to CRT. (cancernetwork.com)
  • Patients must be classified as having intermediate or poor-risk germ cell tumor, as follows: - Intermediate-risk (Modified*) a) Testis or retroperitoneal primary NSGCT with lymph node and/or lung metastasis but without non-pulmonary visceral metastasis AND any of the following pretreatment serum tumor marker (STM) values: i. (stanfordhealthcare.org)
  • In silico analysis suggested that OTUD7B regulation, probably owing to miR-1180 downregulation, may negatively regulate the NF-κB-Lin28 axis which in turn triggers Let-7 microRNA-mediated caspase-3 downregulation, thereby conferring paclitaxel resistance in TNBCs. (oncotarget.com)
  • Ki-67 had a significant association with disease recurrence beyond 3 years and with secondary endocrine resistance in patients with a low RS. (cdc.gov)
  • Conclusions: Nab-P + G in MPC patients can be considered cost-effective for the INHS. (unisr.it)
  • Paclitaxel is under clinical development by Serb and currently in Phase II for Glioblastoma Multiforme (GBM). (pharmaceutical-technology.com)
  • The phase II dose with filgrastim support will be defined as dose escalation of paclitaxel continues. (psu.edu)
  • Eligible patients received CBDCA (area under the curve [AUC] 6 mg/mL/min) on day 1 and nab-PTX (75 mg/m 2 ) on days 1, 8, and 15 every 4 weeks. (elsevierpure.com)
  • Two patients developed grade 1 and one patient developed grade 2 peripheral neuropathy. (johnshopkins.edu)
  • Patients with elevated LDH only will not be included without pathological confirmation of GCT since LDH is a nonspecific marker for GCT and could potentially be elevated in other malignancies such as lymphomas. (stanfordhealthcare.org)
  • It is a sustained-release formulation of paclitaxel. (pharmaceutical-technology.com)
  • We need to remember that every device each has its own unique paclitaxel dose, formulation, and distinct excipient, and as such it needs to be put to the test under the most stringent conditions," Katsanos continued. (tctmd.com)
  • Although as a community we've continued to struggle with this issue of paclitaxel and mortality, VOYAGER PAD does fill many of the gaps and addresses many of the limitations of currently available data," Connie N. Hess, MD , said in reporting results of a prespecified analysis of the trial at the Transcatheter Cardiovascular Research Therapeutics virtual annual meeting. (medscape.com)
  • In the weighted analysis, the all-cause mortality rate at 3.5 years was 12.1% in paclitaxel-coated device recipients and 12.6% in those who didn't get such devices. (medscape.com)
  • The analysis led investigators to conclude that there is no association between mortality risk and paclitaxel-coated device exposure or dose, and should provide reassurance to patients, physicians and regulators on the safety of paclitaxel-coated devices, they say. (cardiovascularnews.com)
  • Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis. (bvsalud.org)
  • A recent aggregate-data meta-analysis reported increased late mortality in patients with peripheral artery disease treated with PTXDs. (bvsalud.org)
  • We performed an individual patient data meta-analysis to evaluate mortality . (bvsalud.org)
  • This individual patient data meta-analysis , based on the most complete available data set of mortality events from PTXD randomized controlled trials, identified an absolute 4.6% increased mortality risk associated with PTXD use. (bvsalud.org)
  • Perhaps, those studies should look more carefully for any signals of patient mortality as well, and further adjust their long-term follow-up protocols accordingly. (tctmd.com)
  • Rapid uptake of the highly lipophilic drug, paclitaxel, limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence. (laborie.com)